| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| phenoxybenzamine | alpha-1a adrenergic receptor | small molecule | NA | drugbank , DGIDB | Pheochromocytoma[MeSHID:D010673] Benign prostatic hypertrophy[MeSHID:D011470] Malignant Hypertension[MeSHID:D006974] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Essential Hypertension[MeSHID:D000075222] |
0.52 | approved | antagonist |
| phenoxybenzamine | alpha-1b adrenergic receptor | small molecule | NA | drugbank | Pheochromocytoma[MeSHID:D010673] Benign prostatic hypertrophy[MeSHID:D011470] Malignant Hypertension[MeSHID:D006974] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Essential Hypertension[MeSHID:D000075222] |
NA | approved | antagonist |
| phenoxybenzamine | alpha-1d adrenergic receptor | small molecule | NA | drugbank | Pheochromocytoma[MeSHID:D010673] Benign prostatic hypertrophy[MeSHID:D011470] Malignant Hypertension[MeSHID:D006974] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Essential Hypertension[MeSHID:D000075222] |
NA | approved | antagonist |
| phenoxybenzamine | alpha-2a adrenergic receptor | small molecule | NA | drugbank | Pheochromocytoma[MeSHID:D010673] Benign prostatic hypertrophy[MeSHID:D011470] Malignant Hypertension[MeSHID:D006974] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Essential Hypertension[MeSHID:D000075222] |
NA | approved | antagonist |
| phenoxybenzamine | alpha-2b adrenergic receptor | small molecule | NA | drugbank , DGIDB | Pheochromocytoma[MeSHID:D010673] Benign prostatic hypertrophy[MeSHID:D011470] Malignant Hypertension[MeSHID:D006974] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Essential Hypertension[MeSHID:D000075222] |
0.23 | approved | antagonist |
| phenoxybenzamine | alpha-2c adrenergic receptor | small molecule | NA | drugbank | Pheochromocytoma[MeSHID:D010673] Benign prostatic hypertrophy[MeSHID:D011470] Malignant Hypertension[MeSHID:D006974] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Essential Hypertension[MeSHID:D000075222] |
NA | approved | antagonist |
| phenoxybenzamine | beta-2 adrenergic receptor | small molecule | NA | drugbank | Pheochromocytoma[MeSHID:D010673] Benign prostatic hypertrophy[MeSHID:D011470] Malignant Hypertension[MeSHID:D006974] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Essential Hypertension[MeSHID:D000075222] |
NA | approved | unknown |
| phenoxybenzamine | calmodulin | small molecule | NA | drugbank | Pheochromocytoma[MeSHID:D010673] Benign prostatic hypertrophy[MeSHID:D011470] Malignant Hypertension[MeSHID:D006974] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Essential Hypertension[MeSHID:D000075222] |
NA | approved | inhibitor |
| phenoxybenzamine | dopamine d2 receptor | NA | Successful target | TTD , DGIDB | Pheochromocytoma[MeSHID:D010673] Benign prostatic hypertrophy[MeSHID:D011470] Malignant Hypertension[MeSHID:D006974] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Essential Hypertension[MeSHID:D000075222] |
0.04 | approved | unknown |
| click here to return to the previous page | ||||||||